Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT04182204
- Locations
- 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT04177108
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇨🇦McGill University; Glen Site; Oncology, Montreal, Quebec, Canada
🇨🇦Royal Victoria Hospital, Barrie, Ontario, Canada
An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT04165135
- Locations
- 🇮🇹
Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy
🇮🇹Az. Osp. Pugliese Ciaccio; S. C. Emofilia, Emostasi e Trombosi, Catanzaro, Calabria, Italy
🇮🇹AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia, Napoli, Campania, Italy
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT04158583
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 73
- Registration Number
- NCT04158648
- Locations
- 🇳🇱
Amsterdam UMC Location AMC, Amsterdam, Netherlands
🇺🇸Childrens Hospital LA, Los Angeles, California, United States
🇺🇸Hemophilia of Georgia Center for Bleeding & Clotting Disorders, Atlanta, Georgia, United States
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2907
- Registration Number
- NCT04158258
- Locations
- 🇦🇷
Instituto Alexander Fleming, Buenos Aires, Argentina
🇦🇷Instituto de Oncología de Rosario, Rosario, Argentina
🇦🇷Sanatorio de la Mujer, Rosario, Argentina
A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT04156646
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT04148911
- Locations
- 🇫🇷
Hopital Avicenne; Cancerologie, Bobigny, France
🇫🇷Institut de Cancérologie de Bourgogne; Oncologie Médicale, Dijon, France
🇫🇷Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie, Levallois-Perret, France
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT04140500
- Locations
- 🇮🇱
Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel
🇮🇱Chaim Sheba medical center, Oncology division, Ramat Gan, Israel
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 634
- Registration Number
- NCT04108156
- Locations
- 🇺🇸
California Retina Consultants., Bakersfield, California, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States